Inhibition of Advanced Glycation and Absence of Galectin-3 Prevent Blood-Retinal Barrier Dysfunction during Short-Term Diabetes

Canning, Paul; Glenn, Josephine V.; Hsu, Daniel K.; Liu, Fu-Tong; Gardiner, Tom A.; Stitt, Alan W.

doi:https://doi.org/10.1155/2007/51837

Journal of Diabetes Research

On this page

Abstract References Copyright Related Articles

Special Issue

Diabetic Retinopathy: From Pathogenesis to Treatment

View this Special Issue

Research Article | Open Access

Volume 2007 | Article ID 051837 | https://doi.org/10.1155/2007/51837

Inhibition of Advanced Glycation and Absence of Galectin-3 Prevent Blood-Retinal Barrier Dysfunction during Short-Term Diabetes

Paul Canning,¹Josephine V. Glenn,¹Daniel K. Hsu,²Fu-Tong Liu,²Tom A. Gardiner,¹and Alan W. Stitt¹

Academic Editor: Subrata Chakrabarti

Received22 Dec 2006

Accepted02 Feb 2007

Published05 Apr 2007

Abstract

Breakdown of the inner blood-retinal barrier (iBRB) occurs early in diabetes and is central to the development of sight-threatening diabetic macular edema (DME) as retinopathy progresses. In the current study, we examined how advanced glycation end products (AGEs) forming early in diabetes could modulate vasopermeability factor expression in the diabetic retina and alter inter-endothelial cell tight junction (TJ) integrity leading to iBRB dysfunction. We also investigated the potential for an AGE inhibitor to prevent this acute pathology and examined a role of the AGE-binding protein galectin-3 (Gal-3) in AGE-mediated cell retinal pathophysiology. Diabetes was induced in C57/BL6 wild-type (WT) mice and in Gal-3−/− transgenic mice. Blood glucose was monitored and AGE levels were quantified by ELISA and immunohistochemistry. The diabetic groups were subdivided, and one group was treated with the AGE-inhibitor pyridoxamine (PM) while separate groups of WT and Gal-3−/− mice were maintained as nondiabetic controls. iBRB integrity was assessed by Evans blue assay alongside visualisation of TJ protein complexes via occludin-1 immunolocalization in retinal flat mounts. Retinal expression levels of the vasopermeability factor VEGF were quantified using real-time RT-PCR and ELISA. WT diabetic mice showed significant AGE -immunoreactivity in the retinal microvasculature and also showed significant iBRB breakdown (P<.005). These diabetics had higher VEGF mRNA and protein expression in comparison to controls (P<.01). PM-treated diabetics had normal iBRB function and significantly reduced diabetes-mediated VEGF expression. Diabetic retinal vessels showed disrupted TJ integrity when compared to controls, while PM-treated diabetics demonstrated near-normal configuration. Gal-3−/− mice showed significantly less diabetes-mediated iBRB dysfunction, junctional disruption, and VEGF expression changes than their WT counterparts. The data suggests an AGE-mediated disruption of iBRB via upregulation of VEGF in the diabetic retina, possibly modulating disruption of TJ integrity, even after acute diabetes. Prevention of AGE formation or genetic deletion of Gal-3 can effectively prevent these acute diabetic retinopathy changes.

References

R. J. Antcliff and J. Marshall, “The pathogenesis of edema in diabetic maculopathy,” Seminars in Ophthalmology, vol. 14, no. 4, pp. 223–232, 1999.
View at: Google Scholar
C. Engler, B. Krogsaa, and H. Lund-Andersen, “Blood-retina barrier permeability and its relation to the progression of diabetic retinopathy in type 1 diabetes. An 8-year follow-up study,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 229, no. 5, pp. 442–446, 1991.
View at: Publisher Site | Google Scholar
B. Sander, M. Larsen, C. Engler et al., “Diabetic macular oedema: a comparison of vitreous fluorometry, angiography, and retinopathy,” British Journal of Ophthalmology, vol. 86, no. 3, pp. 316–320, 2002.
View at: Publisher Site | Google Scholar
G. L. Trick, J. Liggett, J. Levy et al., “Dynamic contrast enhanced MRI in patients with diabetic macular edema: initial results,” Experimental Eye Research, vol. 81, no. 1, pp. 97–102, 2005.
View at: Publisher Site | Google Scholar
M. S. Roy, M. J. Podgor, P. Bungay, G. Grunberger, J. Carl, and D. Ellis, “Posterior vitreous fluorophotometry in diabetic patients with minimal or no retinopathy,” Retina, vol. 7, no. 3, pp. 170–176, 1987.
View at: Publisher Site | Google Scholar
J. Cunha-Vaz, C. Lobo, J. C. Sousa, B. Oliveiros, E. Leite, and J. R. Faria de Abreu, “Progression of retinopathy and alteration of the blood-retinal barrier in patients with type 2 diabetes: a 7-year prospective follow-up study,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 236, no. 4, pp. 264–268, 1998.
View at: Publisher Site | Google Scholar
A. B. El-Remessy, M. A. Behzadian, G. Abou-Mohamed, T. Franklin, R. W. Caldwell, and R. B. Caldwell, “Experimental diabetes causes breakdown of the blood-retina barrier by a mechanism involving tyrosine nitration and increases in expression of vascular endothelial growth factor and urokinase plasminogen activator receptor,” American Journal of Pathology, vol. 162, no. 6, pp. 1995–2004, 2003.
View at: Google Scholar
T. Qaum, Q. Xu, A. M. Joussen et al., “VEGF-initiated blood-retinal barrier breakdown in early diabetes,” Investigative Ophthalmology and Visual Science, vol. 42, no. 10, pp. 2408–2413, 2001.
View at: Google Scholar
R. H. Amin, R. N. Frank, A. Kennedy, D. Eliott, J. E. Puklin, and G. W. Abrams, “Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy,” Investigative Ophthalmology and Visual Science, vol. 38, no. 1, pp. 36–47, 1997.
View at: Google Scholar
D. A. Antonetti, A. J. Barber, L. A. Hollinger, E. B. Wolpert, and T. W. Gardner, “Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors,” Journal of Biological Chemistry, vol. 274, no. 33, pp. 23463–23467, 1999.
View at: Publisher Site | Google Scholar
A. J. Barber and D. A. Antonetti, “Mapping the blood vessels with paracellular permeability in the retinas of diabetic rats,” Investigative Ophthalmology and Visual Science, vol. 44, no. 12, pp. 5410–5416, 2003.
View at: Publisher Site | Google Scholar
S. Ishida, T. Usui, K. Yamashiro et al., “VEGF164 is proinflammatory in the diabetic retina,” Investigative Ophthalmology and Visual Science, vol. 44, no. 5, pp. 2155–2162, 2003.
View at: Publisher Site | Google Scholar
L. P. Aiello, S.-E. Bursell, A. Clermont et al., “Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective $ß$ -isoform-selective inhibitor,” Diabetes, vol. 46, no. 9, pp. 1473–1480, 1997.
View at: Google Scholar
R. Rota, C. Chiavaroli, R. P. Garay, and P. Hannaert, “Reduction of retinal albumin leakage by the antioxidant calcium dobesilate in streptozotocin-diabetic rats,” European Journal of Pharmacology, vol. 495, no. 2-3, pp. 217–224, 2004.
View at: Publisher Site | Google Scholar
A. K. H. Cheung, M. K. L. Fung, A. C. Y. Lo et al., “Aldose reductase deficiency prevents diabetes-induced blood-retinal barrier breakdown, apoptosis, and glial reactivation in the retina of db/db mice,” Diabetes, vol. 54, no. 11, pp. 3119–3125, 2005.
View at: Google Scholar
I. G. Obrosova, A. G. Minchenko, R. Vasupuram et al., “Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats,” Diabetes, vol. 52, no. 3, pp. 864–871, 2003.
View at: Google Scholar
S. R. Thorpe and J. W. Baynes, “Maillard reaction products in tissue proteins: new products and new perspectives,” Amino Acids, vol. 25, no. 3-4, pp. 275–281, 2003.
View at: Publisher Site | Google Scholar
H.-P. Hammes, A. Alt, T. Niwa et al., “Differential accumulation of advanced glycation end products in the course of diabetic retinopathy,” Diabetologia, vol. 42, no. 6, pp. 728–736, 1999.
View at: Publisher Site | Google Scholar
N. Karachalias, R. Babaei-Jadidi, N. Ahmed, and P. J. Thornalley, “Accumulation of fructosyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats,” Biochemical Society Transactions, vol. 31, part 6, pp. 1423–1425, 2003.
View at: Google Scholar
A. W. Stitt, Y. M. Li, T. A. Gardiner, R. Bucala, D. B. Archer, and H. Vlassara, “Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats,” American Journal of Pathology, vol. 150, no. 2, pp. 523–531, 1997.
View at: Google Scholar
A. W. Stitt, T. Bhaduri, C. B. T. McMullen, T. A. Gardiner, and D. B. Archer, “Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats,” Molecular Cell Biology Research Communications, vol. 3, no. 6, pp. 380–388, 2000.
View at: Publisher Site | Google Scholar
A. W. Stitt, T. A. Gardiner, N. L. Anderson et al., “The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes,” Diabetes, vol. 51, no. 9, pp. 2826–2832, 2002.
View at: Google Scholar
T. A. Gardiner, H. R. Anderson, and A. W. Stitt, “Inhibition of advanced glycation end-products protects against retinal capillary basement membrane expansion during long-term diabetes,” Journal of Pathology, vol. 201, no. 2, pp. 328–333, 2003.
View at: Publisher Site | Google Scholar
A. Bierhaus, M. A. Hofmann, R. Ziegler, and P. P. Nawroth, “AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept,” Cardiovascular Research, vol. 37, no. 3, pp. 586–600, 1998.
View at: Publisher Site | Google Scholar
A. M. Schmidt, S. D. Yan, S. F. Yan, and D. M. Stern, “The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses,” Journal of Clinical Investigation, vol. 108, no. 7, pp. 949–955, 2001.
View at: Publisher Site | Google Scholar
A. W. Stitt, C. McGoldrick, A. Rice-McCaldin et al., “Impaired retinal angiogenesis in diabetes: role of advanced glycation end products and galectin-3,” Diabetes, vol. 54, no. 3, pp. 785–794, 2005.
View at: Google Scholar
M. Lu, M. Kuroki, S. Amano et al., “Advanced glycation end products increase retinal vascular endothelial growth factor expression,” Journal of Clinical Investigation, vol. 101, no. 6, pp. 1219–1224, 1998.
View at: Google Scholar
S.-I. Yamagishi, H. Yonekura, Y. Yamamoto et al., “Advanced glycation end products-driven angiogenesis in vitro: induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor,” Journal of Biological Chemistry, vol. 272, no. 13, pp. 8723–8730, 1997.
View at: Publisher Site | Google Scholar
S. McFarlane, J. V. Glenn, A. M. Lichanska, D. A. C. Simpson, and A. W. Stitt, “Characterisation of the advanced glycation endproduct receptor complex in the retinal pigment epithelium,” British Journal of Ophthalmology, vol. 89, no. 1, pp. 107–112, 2005.
View at: Publisher Site | Google Scholar
K. Otero, F. Martínez, A. Beltrán et al., “Albumin-derived advanced glycation end-products trigger the disruption of the vascular endothelial cadherin complex in cultured human and murine endothelial cells,” Biochemical Journal, vol. 359, part 3, pp. 567–574, 2001.
View at: Publisher Site | Google Scholar
G. Leto, F. Pricci, L. Amadio et al., “Increased retinal endothelial cell monolayer permeability induced by the diabetic milieu: role of advanced non-enzymatic glycation and polyol pathway activation,” Diabetes/Metabolism Research and Reviews, vol. 17, no. 6, pp. 448–458, 2001.
View at: Publisher Site | Google Scholar
T. C. B. Moore, J. E. Moore, Y. Kaji et al., “The role of advanced glycation end products in retinal microvascular leukostasis,” Investigative Ophthalmology and Visual Science, vol. 44, no. 10, pp. 4457–4464, 2003.
View at: Publisher Site | Google Scholar
D. K. Hsu, R.-Y. Yang, Z. Pan et al., “Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses,” American Journal of Pathology, vol. 156, no. 3, pp. 1073–1083, 2000.
View at: Google Scholar
O. T. Cox, D. A. C. Simpson, A. W. Stitt, and T. A. Gardiner, “Sources of PDGF expression in murine retina and the effect of short-term diabetes,” Molecular Vision, vol. 10, no. 9, pp. 665–672, 2003.
View at: Google Scholar
B. Brankin, M. Campbell, P. Canning, T. A. Gardiner, and A. W. Stitt, “Endostatin modulates VEGF-mediated barrier dysfunction in the retinal microvascular endothelium,” Experimental Eye Research, vol. 81, no. 1, pp. 22–31, 2005.
View at: Publisher Site | Google Scholar
D. A. Simpson, S. Feeney, C. Boyle, and A. W. Stitt, “Retinal VEGF mRNA measured by SYBR green I fluorescence: a versatile approach to quantitative PCR,” Molecular Vision, vol. 6, pp. 178–183, 2000.
View at: Google Scholar
A. M. Joussen, V. Poulaki, N. Mitsiades et al., “Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF- $a$ suppression,” The FASEB Journal, vol. 16, no. 3, pp. 438–440, 2002.
View at: Google Scholar
A. M. Joussen, V. Poulaki, W. Qin et al., “Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo,” American Journal of Pathology, vol. 160, no. 2, pp. 501–509, 2002.
View at: Google Scholar
A. W. Stitt and T. M. Curtis, “Advanced glycation and retinal pathology during diabetes,” Pharmacological Reports, vol. 57, supplement, pp. 156–168, 2005.
View at: Google Scholar
P. S. Padayatti, C. Jiang, M. A. Glomb, K. Uchida, and R. H. Nagaraj, “High concentrations of glucose induce synthesis of argpyrimidine in retinal endothelial cells,” Current Eye Research, vol. 23, no. 2, pp. 106–115, 2001.
View at: Publisher Site | Google Scholar
D. Yao, T. Taguchi, T. Matsumura et al., “Methylglyoxal modification of mSin3A links glycolysis to angiopoietin-2 transcription,” Cell, vol. 124, no. 2, pp. 275–286, 2006.
View at: Publisher Site | Google Scholar
I. Giardino, D. Edelstein, and M. Brownlee, “Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes,” Journal of Clinical Investigation, vol. 94, no. 1, pp. 110–117, 1994.
View at: Google Scholar
A. W. Stitt, U. Chakravarthy, D. B. Archer, and T. A. Gardiner, “Increased endocytosis in retinal vascular endothelial cells grown in high glucose medium is modulated by inhibitors of nonenzymatic glycosylation,” Diabetologia, vol. 38, no. 11, pp. 1271–1275, 1995.
View at: Publisher Site | Google Scholar
D. S. Fosmark, P. A. Torjesen, B. K. Kilhovd et al., “Increased serum levels of the specific advanced glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus,” Metabolism, vol. 55, no. 2, pp. 232–236, 2006.
View at: Publisher Site | Google Scholar
D. J. McKenna, J. Nelson, and A. W. Stitt, “Advanced glycation alters expression of the 67kDa laminin receptor in retinal microvascular endothelial cells,” Life Sciences, vol. 68, no. 24, pp. 2695–2703, 2001.
View at: Publisher Site | Google Scholar
H.-P. Hammes, D. Strodter, A. Weiss, R. G. Bretzel, K. Federlin, and M. Brownlee, “Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model,” Diabetologia, vol. 38, no. 6, pp. 656–660, 1995.
View at: Publisher Site | Google Scholar
N. L. Alderson, M. E. Chachich, N. N. Youssef et al., “The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats,” Kidney International, vol. 63, no. 6, pp. 2123–2133, 2003.
View at: Publisher Site | Google Scholar
R. H. Nagaraj, P. Sarkar, A. Mally, K. M. Biemel, M. O. Lederer, and P. S. Padayatti, “Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyridoxamine and methylglyoxal,” Archives of Biochemistry and Biophysics, vol. 402, no. 1, pp. 110–119, 2002.
View at: Publisher Site | Google Scholar
C. Treins, S. Giorgetti-Peraldi, J. Murdaca, and E. Van Obberghen, “Regulation of vascular endothelial growth factor expression by advanced glycation end products,” Journal of Biological Chemistry, vol. 276, no. 47, pp. 43836–43841, 2001.
View at: Publisher Site | Google Scholar
J. Dumic, S. Dabelic, and M. Flögel, “Galectin-3: an open-ended story,” Biochimica et Biophysica Acta (BBA)—General Subjects, vol. 1760, no. 4, pp. 616–635, 2006.
View at: Publisher Site | Google Scholar
H. Vlassara, R. Bucala, and L. Striker, “Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging,” Laboratory Investigation, vol. 70, no. 2, pp. 138–151, 1994.
View at: Google Scholar
W. Zhu, H. Sano, R. Nagai, K. Fukuhara, A. Miyazaki, and S. Horiuchi, “The role of galectin-3 in endocytosis of advanced glycation end products and modified low density lipoproteins,” Biochemical and Biophysical Research Communications, vol. 280, no. 4, pp. 1183–1188, 2001.
View at: Publisher Site | Google Scholar
G. Pugliese, F. Pricci, G. Leto et al., “The diabetic milieu modulates the advanced glycation end product-receptor complex in the mesangium by inducing or upregulating galectin-3 expression,” Diabetes, vol. 49, no. 7, pp. 1249–1257, 2000.
View at: Google Scholar
G. Pugliese, F. Pricci, C. Iacobini et al., “Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice,” The FASEB Journal, vol. 15, no. 13, pp. 2471–2479, 2001.
View at: Publisher Site | Google Scholar
F.-T. Liu, R. J. Patterson, and J. L. Wang, “Intracellular functions of galectins,” Biochimica et Biophysica Acta (BBA)—General Subjects, vol. 1572, no. 2-3, pp. 263–273, 2002.
View at: Publisher Site | Google Scholar
C. Colnot, M.-A. Ripoche, G. Milon, X. Montagutelli, P. R. Crocker, and F. Poirier, “Maintenance of granulocyte numbers during acute peritonitis is defective in galectin-3-null mutant mice,” Immunology, vol. 94, no. 3, pp. 290–296, 1998.
View at: Publisher Site | Google Scholar
H. Sano, D. K. Hsu, J. R. Apgar et al., “Critical role of galectin-3 in phagocytosis by macrophages,” Journal of Clinical Investigation, vol. 112, no. 3, pp. 389–397, 2003.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2007 Paul Canning et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation Order printed copies

Views

618

Downloads

2414

Citations